Midtveisevaluering - Brage Brakedal
Midtveisevaluering for ph.d.-graden ved Universitetet i Bergen for kandidat Brage Brakedal
Brage Brakedal er tilknyttet Klinisk institutt 1. Veiledere er Kristoffer Haugarvoll, Charalampos Tzoulis og Ole-Bjørn Tysnes.
Identifying drugs associated with reduced risk of Parkinson's disease and their synergistic effects using the Norwegian Prescription Database
Parkinson’s Disease is the second most common neurodegenerative disease. The pathophysiological mechanisms of Parkinson’s Disease (PD) remains elusive and there are no disease-modifying or protective drugs, just symptomatic. The goal for the dissertation is to examine if there are commonly used drugs that either decrease or increase the risk of incidence Parkinson’s disease. Using the Norwegian drug prescription database, we are able to identify drugs used prior to PD diagnosis and see if drugs are associated with reduced or increased risk of PD. A randomized double-blinded clinical phase 1 study is performed, the NADPARK study, to examine the metabolism, viability and safety of Nicotinamide Riboside (a vitamin B3 form) that has been postulated to act neuroprotective for PD patients and could possibly present to be a neuroprotective disease-modifying drug. Currently a national clinical phase 2 study is undergoing to test this hypothesis.
We have identified that glitazones, an anti-diabetic drug, is associated with an approximate 30% risk of PD incidence. We also found that the commonly used simvastatin was also associated with reduced risk of Parkinson’s disease. We have not found that the use of non-steroidal anti-inflammatory drugs (NSAIDS) are associated with Parkinson’s disease. Analysis of the NADPARK study datais currently being performed.